The Fetal Medicine Foundation 22nd World Congress in Fetal Medicine, Prague, Czechia
Abstracts
 
  • Aneuploidies
  • Genetics
  • Defects
    • Brain
    • Face
    • Heart
    • Lungs
    • Gastrointestinal
    • Genitourinary
    • Spine
    • Skeleton
    • Syndromes
    • Other
  • Fetal therapy
  • Infections
  • Maternal medicine
  • Preeclampsia
  • Gestational diabetes
  • Preterm birth
  • Labor
  • Growth
  • Obstretrics
  • Multiple pregnancies
  • Placenta
  • Artificial Intelligence
  • Other

Preeclampsia

  1. A case of severe preeclampsia in a fit and healthy primigravida during 33/40 View pdf
  2. A Combined First-Trimester Risk Approach for Preterm Preeclampsia and Preterm Small-for-Gestational-Age: Defining a High-Risk Placental Dysfunction Population View pdf
  3. A Window to Preeclampsia: Third Trimester Insights from Ophthalmic Artery Doppler View pdf
  4. Angiogenic Imbalance During Pregnancy and Memory Impairment 3–6 Years Postpartum View pdf
  5. Aspirin delays preeclampsia in women with chronic hypertension View pdf
  6. Aspirin delays the gestational age at diagnosis of and delivery with preeclampsia: evidence from a randomized clinical trial in Asia View pdf
  7. Aspirin for the prevention of preeclampsia: the role of first-trimester risk View pdf
  8. Association between the sFlt-1/PlGF ratio and ophthalmic artery Doppler in near-term pregnancies: a potential surrogate for angiogenic imbalance View pdf
  9. Cardiovascular Adaptation in pregnancies at High-Risk of Preeclampsia: A Longitudinal Study from Early to Late Pregnancy View pdf
  10. Characterizing the Association Between Hypertriglyceridemia and the Risk of Pre-Eclampsia: Predictors and Contributing Factors View pdf
  11. Clinical utility of the sFlt-1/PlGF ratio at 26 weeks for estimating the risk of preeclampsia, fetal growth restriction and placental abruption in high-risk patients View pdf
  12. Comparing Acute Fatty Liver Of Pregnancy From Hellp Syndrome. New Diagnostic Approach Using Serological Markers View pdf
  13. Comparison Of Glycosylated Fibronectin Point-Of-Care Test With SFLT/PLGF Ratio For Assessment Of Preeclampsia View pdf
  14. Cost-benefit analysis of adding PlGF in screening for PE View pdf
  15. Daytime Variations in Urinary Protein to Creatinine Ratio among Pregnant Women with and without Hypertensive Disorders View pdf
  16. Decoding Preeclampsia: Exploring Placental Molecular Signatures Across Subtypes View pdf
  17. Dual Prediction of Preeclampsia by Third Trimester Congo Red Test and Pro- and Anti-Angiogenic Markers and their Cost Benefit Analysis In The Israeli Healthcare System View pdf
  18. Early-onset preeclampsia with and without prophylactic aspirin; is there a real difference in pregnancy outcomes? View pdf
  19. EASIX (endothelial activation and stress index) for prediction of adverse maternal and perinatal outcomes in preeclampsia View pdf
  20. Effect of aspirin on maternal hemodynamics in Chinese women at high-risk for preeclampsia: a longitudinal study View pdf
  21. Effect of Low Molecular Weight Heparin (LMWH) in patients with Fetal Growth Restriction (FGR) View pdf
  22. Effect of parity on maternal hemodynamic profile during pregnancy: a longitudinal study View pdf
  23. EHealth interventions for hypertensive disorders of pregnancy and preeclampsia View pdf
  24. Epidemiology and associated factors of superimposed preeclampsia in pregnant women with chronic hypertension: A retrospective multicenter cohort study View pdf
  25. Evaluating PlGF Before 11 Weeks: Can Early First-Trimester Levels Predict Preeclampsia? View pdf
  26. Extra Virgin Olive Oil and preeclampsia: association to blood pressure, angiogenic profile and uterine Doppler View pdf
  27. Fetal Growth and Doppler after Aspirin Discontinuation View pdf
  28. Fetal growth restriction and sFlt-1/PlGF ratio in severe preeclampsia View pdf
  29. Fetal Medicine Foundation first trimester preeclampsia risk estimate: A window into long-term maternal cardiovascular health View pdf
  30. First-trimester screening for preeclampsia in women carrying a fetus with a major congenital heart defect View pdf
  31. First-Trimester sequential screening for preeclampsia using angiogenic factors: A prospective, multicenter, real-world clinical practice study (CRISP) View pdf
  32. Functional differences in the placenta of pregnancies affected by preeclampsia or fetal growth restriction View pdf
  33. Gestational metabolic shift signifies the effectiveness of aspirin treatment for women at risk of preeclampsia View pdf
  34. High Risk of Preeclampsia: Is It Only Preeclampsia We Need to Worry About? View pdf
  35. How does the FMF first-trimester risk assessment for preterm preeclampsia perform in women with maternal and obstetric high-risk factors who are eligible for aspirin prophylaxis according to current Danish guidelines? View pdf
  36. Impact of aspirin and dietary salicylates on biochemical markers of preeclampsia in rats View pdf
  37. Implantation on- a chip model in preeclampsia View pdf
  38. Implementation of Real-Time Placental Growth Factor (PlGF) in a Tertiary Canadian Centre: Association with Ultrasound findings and Perinatal Outcomes View pdf
  39. Inverting the pyramid” of specialist antenatal care: Reducing preterm preeclampsia with the IMAP (Initial Maternity Assessment and Planning) Service View pdf
  40. Low Molecular Weight Heparin (LMWH) in pregnancies with Fetal Growth Restriction (FGR) and Normal Fetal Growth (NFG) with suspected placental dysfunction View pdf
  41. Machine learning to Improve Prediction of Late-Onset Preeclampsia View pdf
  42. Maternal and perinatal outcomes in non-severe late preterm preeclampsia managed with PlGF: real-life validation of the MAP trial View pdf
  43. Midtrimester arterial stiffness among women at high-risk for preterm preeclampsia View pdf
  44. Ophthalmic Artery Doppler and Carotid Intima-Media Thickness 3 to 6 Years Postpartum in Women With and Without a History of Placental Insufficiency View pdf
  45. Pentraxins 3 levels in pregnant women diagnosed with preeclampsia and their relationship with the severity of the condition View pdf
  46. Performance of an intensive follow-up strategy for patients with a positive first-trimester screening of preterm preeclampsia View pdf
  47. Perinatal Outcomes associated with Maternal Placental Growth Factor (PlGF) collected from 12w to 20w6d View pdf
  48. Peripartum Cardiomyopathy Presenting as Acute Heart Failure in a Preeclamptic Postpartum Patient: A Case Report View pdf
  49. Posterior Reversible Encephalopathy Syndrome in the Immediate Postpartum Period View pdf
  50. Prediction of Fetal Death in Preterm Preeclampsia Using Fetal Sex, Placental Growth Factor and Gestational Age View pdf
  51. Prediction of preeclampsia: Blood pressure measured at 6-10 weeks in primary care versus 11-14 weeks at first-trimester ultrasound View pdf
  52. Predictive performance of the Fetal Medicine Foundation first trimester screening for preeclampsia in pregnancies following assisted reproduction View pdf
  53. Predictive value of mean platelet volume, neutrophil-to-lymphocyte ratio and platelet- to-lymphocyte ratio in the second trimester blood test for preeclampsia View pdf
  54. Predictive value of mean platelet volume, neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio in the first trimester blood test for preeclampsia View pdf
  55. Predictors Of Blood Pressure And Hypertensive Syndromes In Brazilian Pregnant Women With Previous Diabetes Mellitus View pdf
  56. Preeclampsia prediction by machine learning in twin pregnancies View pdf
  57. Prophylactic Aspirin Treatment for Preeclampsia Prevention in Dichorionic-Diamniotic Twin Pregnancies View pdf
  58. Refractory epistaxis in pregnancy potentially induced by the use of aspirin: Case report View pdf
  59. Retroplacental hematoma in 18. weeks of pregnancy with subsequent development of severe preeclampsia and fetal growth restriction View pdf
  60. Risk of Superimposed Preeclampsia and Adverse Maternal and Perinatal Outcomes in Pregnant Women with Chronic Hypertension View pdf
  61. Role of Resistin in Early Prediction of Preeclampsia during the 11-13.4 weeks scan View pdf
  62. Soluble fms-like tyrosine kinase-1 (sFlt-1) before 11 weeks for the prediction of preterm and early preeclampsia View pdf
  63. The American College of Cardiology / American Heart Association classification of chronic hypertension in pregnancy has better clinical applicability and risk assessment than the traditional high and low risk hypertension approach – lessons from a populat View pdf
  64. The effect of diabetes mellitus type 1 (T1DM) in pregnancy on the levels of biomarkers of preeclampsia: results of a single-centre prospective study View pdf
  65. The impact of 1st trimester PE screening combined with 2nd trimester PTB screening: the PREVENTION-pilot study View pdf
  66. The impacts of the mode of conception on preeclampsia risk prediction and pregnancy outcomes in twin pregnancies View pdf
  67. The Placenta And Its Location In Determining The Clinical Picture Of Preeclampsia View pdf
  68. The role of vascular endothelial growth factor (VEGF) and soluble receptor of vascular endothelial growth factor (VEGF-R) in the ethiopathogenesis of preeclampsia View pdf
  69. Third trimester screening for preeclampsia in twins: comparative performance of FMF algorithm, Roche and Quidel triages View pdf
  70. Ultra-processed foods consumption and risk of preeclampsia View pdf
  71. Uterine artery hemodynamics and vitamin D status: a new opportunity for predicting and preventing preeclampsia? View pdf
75577124726670927625725275967223771874867434713373437330697271237640755669117033699871426876689477207151733575957129745773747644719373727585689570936993721669997286712177027091745974376996765773987065763271307180717973947037745573917111711469597191702873387653758969377712707371997574
© 2025 The Fetal Medicine Foundation